Abstract
The quadrivalent human papillomavirus (HPV) vaccine currently being delivered to Australian women aged 12-26 years under the National HPV Vaccination Program promises to substantially reduce the incidence of genital warts. We review what is known about the burden of genital warts among Australian women. Incidence appears to peak among women aged 20-24 years, of whom 1.4% report genital warts in the previous year and who are hospitalised for treatment at a rate of 26 per 100,000. A surveillance system capable of documenting any decrease in the incidence of genital warts and recurrent respiratory papillomatosis after vaccination is urgently required.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
